Journal
AMERICAN JOURNAL OF HUMAN GENETICS
Volume 81, Issue 6, Pages 1186-1200Publisher
CELL PRESS
DOI: 10.1086/522611
Keywords
-
Categories
Funding
- Cancer Research UK [10118] Funding Source: Medline
- NCI NIH HHS [U01 CA086389, R01 CA083855, N02CP11019, P50 CA116201, 5UO1 CA86389, R01 CA074415, CA-95-003, P50-CA116201, N02-CP-11019-50, R01-CA74415, R01-CA102776, R01 CA102776, R01-CA083855] Funding Source: Medline
- NCRR NIH HHS [M01 RR000043, MO1 RR00043] Funding Source: Medline
Ask authors/readers for more resources
RAD51 is an important component of double-stranded DNA-repair mechanisms that interacts with both BRCA1 and BRCA2. A single-nucleotide polymorphism (SNP) in the 5' untranslated region (UTR) of RAD51, 135G -> C, has been suggested as a possible modifier of breast cancer risk in BRCA1 and BRCA2 mutation carriers. We pooled genotype data for 8,512 female mutation carriers from 19 studies for the RAD51 135G -> C SNP. We found evidence of an increased breast cancer risk in CC homozygotes (hazard ratio [HR] 1.92 [95% confidence interval {Cl} 1.25-2.94) but not in heterozygotes (HR 0.95 [95% Cl 0.83-1.07]; P =.002, by heterogeneity test with 2 degrees of freedom [df]). When BRCA1 and BRCA2 mutation carriers were analyzed separately, the increased risk was statistically significant only among BRCA2 mutation carriers, in whom we observed HRs of 1.17 (95% Cl 0.91-1.51) among heterozygotes and 3.18 (95% Cl 1.39-7.27) among rare homozygotes (P =.0007, by heterogeneity test with 2 df). In addition, we determined that the 135G -> C variant affects RAD51 splicing within the 5' UTR. Thus, 135G -> C may modify the risk of breast cancer in BRCA2 mutation carriers by altering the expression of RAD51. RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/ 2 mutation carriers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available